Details for New Drug Application (NDA): 208619
✉ Email this page to a colleague
The generic ingredient in LEVETIRACETAM IN SODIUM CHLORIDE is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-seven suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.
Summary for 208619
| Tradename: | LEVETIRACETAM IN SODIUM CHLORIDE |
| Applicant: | Fresenius Kabi Usa |
| Ingredient: | levetiracetam |
| Patents: | 0 |
Pharmacology for NDA: 208619
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 208619
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LEVETIRACETAM IN SODIUM CHLORIDE | levetiracetam | INJECTABLE;INTRAVENOUS | 208619 | ANDA | Fresenius Kabi USA, LLC | 65219-042 | 65219-042-71 | 24 BAG in 1 CARTON (65219-042-71) / 100 mL in 1 BAG (65219-042-21) |
| LEVETIRACETAM IN SODIUM CHLORIDE | levetiracetam | INJECTABLE;INTRAVENOUS | 208619 | ANDA | Fresenius Kabi USA, LLC | 65219-044 | 65219-044-71 | 24 BAG in 1 CARTON (65219-044-71) / 100 mL in 1 BAG (65219-044-21) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 500MG/100ML (5MG/ML) | ||||
| Approval Date: | Jan 31, 2023 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 1GM/100ML (10MG/ML) | ||||
| Approval Date: | Jan 31, 2023 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 1.5GM/100ML (15MG/ML) | ||||
| Approval Date: | Jan 31, 2023 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
